A. Suri

发表

Assessment of Vedolizumab Disease‐Drug‐Drug Interaction Potential in Patients With Inflammatory Bowel Diseases

J. Aubrecht, J. Schneider, P. Gulati, 2020, Clinical pharmacology in drug development.

Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures.

J. Rosenstock, B. Silverman, D. Muchmore, 2007, Diabetes technology & therapeutics.

Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles

K. Venkatakrishnan, M. Lehnert, T. Takubo, 2016, Clinical and translational science.

Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

Stephen X. Zhang, K. Neville, T. Klingebiel, 2018, The Lancet. Haematology.

Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment.

H. Iwata, Y. Fujiwara, S. Takashima, 2009, Japanese journal of clinical oncology.

Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer

M. Gross, J. Hainsworth, L. Hart, 2014, Clinical Cancer Research.

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study

K. Venkatakrishnan, D. Mould, C. Endres, 2019, Clinical pharmacology and therapeutics.

Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study

K. Venkatakrishnan, D. Mould, G. Jang, 2018, Clinical pharmacology and therapeutics.

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

J. Sloan, R. Goldberg, S. Alberts, 2005, Cancer Chemotherapy and Pharmacology.

Effect of Omeprazole on the Metabolism of Cilostazol

A. Suri, S. Bramer, 1999, Clinical pharmacokinetics.

Pharmacokinetics of Multiple‐Dose Oral Cilostazol in Middle‐Age and Elderly Men and Women

W. Forbes, A. Suri, S. Bramer, 1998, Journal of clinical pharmacology.

Inhibition of CYP2D6 by Quinidine and its Effects on the Metabolism of Cilostazol

A. Suri, S. Bramer, 1999, Clinical pharmacokinetics.

Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.

R. Neuwirth, M. Colombel, H. Matsui, 2014, The Journal of clinical endocrinology and metabolism.

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer

W. Oh, E. Heath, D. Agus, 2015, Investigational New Drugs.

The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study

Toshio Shimizu, A. Shimomura, K. Yonemori, 2021, Japanese journal of clinical oncology.

Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer

H. Watari, K. Ushijima, N. Tanaka, 2021, Journal of gynecologic oncology.

Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer

A. Okamoto, K. Hasegawa, D. Aoki, 2020, Journal of Gynecologic Oncology.

Effects of CYP3A Inhibition on the Metabolism of Cilostazol

W. Forbes, A. Suri, S. Bramer, 1999, Clinical pharmacokinetics.

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay

G. Smithson, N. Vande Casteele, A. Suri, 2023, Therapeutic drug monitoring.

Assessment of cytochrome P450‐mediated drug–drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation

Chuang Lu, Wen Chyi Shyu, Chuang Lu, 2014, Biopharmaceutics & drug disposition.

Relationships between food effects, patient adherence to treatment, and pharmacokinetics of oral anticancer drugs.

S. Aggarwal, A. Suri, H. Lin, 2014 .

A Phase 1, Randomized, Single‐Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK‐700) in Healthy Male Subjects

D. MacLean, Theresa T. Pham, A. Suri, 2016, Clinical pharmacology in drug development.

Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK‐700) in Healthy Male Subjects: A Phase 1, Open‐Label, Single‐Dose Study

Yuexian Li, S. Prakash, A. Suri, 2016, Clinical pharmacology in drug development.

A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.

S. Clarke, M. Millward, J. Latz, 2005, Lung cancer.

Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride

Gerhard Gründer, Robert F. Dannals, Hayden T. Ravert, 2002, Neuropsychopharmacology.

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

D. Hyman, Geoffrey Kim, Yan Ji, 2018, Clinical and translational science.

Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens

K. Venkatakrishnan, D. Mould, A. Suri, 2020, Journal of clinical pharmacology.

Physiologically based and population PK modeling in optimizing drug development: A predict–learn–confirm analysis

K. Venkatakrishnan, K Venkatakrishnan, C Lu, 2015, Clinical pharmacology and therapeutics.

Effect of Upper Respiratory Tract Infection on AIR Inhaled Insulin Pharmacokinetics and Glucodynamics in Healthy Subjects

F. Tibaldi, Soomin Park, A. Peña, 2008, Clinical pharmacology and therapeutics.

Erratum: Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11C]Raclopride⋆

D. Wong, R. Dannals, H. Ravert, 2002, Neuropsychopharmacology.

Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective

C. Endres, K. Liao, M. Walles, 2021, Clinical pharmacology and therapeutics.

Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects.

R. Branch, M. Knadler, S. Reddy, 2005, International journal of clinical pharmacology and therapeutics.

Pharmacodynamic Evaluation of Codeine Using Tooth Pulp Evoked Potentials

H Derendorf, H. Derendorf, B. L. Grundy, 1996, Journal of clinical pharmacology.